Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Deborah T. Blumenthal, Thierry Gorlia, Mark R. Gilbert, Michelle M. Kim, L. Burt Nabors, Warren P. Mason, Monika E. Hegi, Peixin Zhang, Vassilis Golfinopoulos, James R. Perry, Do Hyun Nam, Sara C. Erridge, Benjamin W. Corn, Rene O. Mirimanoff, Paul D. Brown, Brigitta G. Baumert, Minesh P. Mehta, Martin J. van den Bent, David A. Reardon, Michael WellerRoger Stupp

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1119-1126
Number of pages8
JournalNeuro-oncology
Volume19
Issue number8
DOIs
Publication statusPublished - Aug 2017

Keywords

  • RANDOMIZED PHASE-III
  • MOLECULAR-MECHANISMS
  • STANDARD TREATMENT
  • MALIGNANT GLIOMAS
  • GRADE GLIOMAS
  • OPEN-LABEL
  • TRIAL
  • RADIOTHERAPY
  • TOXICITY
  • BEVACIZUMAB

Cite this

Blumenthal, D. T., Gorlia, T., Gilbert, M. R., Kim, M. M., Nabors, L. B., Mason, W. P., Hegi, M. E., Zhang, P., Golfinopoulos, V., Perry, J. R., Nam, D. H., Erridge, S. C., Corn, B. W., Mirimanoff, R. O., Brown, P. D., Baumert, B. G., Mehta, M. P., van den Bent, M. J., Reardon, D. A., ... Stupp, R. (2017). Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro-oncology, 19(8), 1119-1126. https://doi.org/10.1093/neuonc/nox025